Marco Massari to Aged, 80 and over
This is a "connection" page, showing publications Marco Massari has written about Aged, 80 and over.
Connection Strength
0.053
-
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. Rheumatology (Oxford). 2021 10 09; 60(SI):SI25-SI36.
Score: 0.007
-
The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients. PLoS One. 2021; 16(5):e0251768.
Score: 0.007
-
Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Death in Patients Hospitalised with COVID-19: A Retrospective Italian Cohort Study of 43,000 Patients. Drug Saf. 2020 12; 43(12):1297-1308.
Score: 0.006
-
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med. 2020 10 21; 18(1):405.
Score: 0.006
-
Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 06 11; 382(24):2327-2336.
Score: 0.006
-
The potential impact of multidimesional geriatric assessment in the social security system. Aging Clin Exp Res. 2018 Oct; 30(10):1225-1232.
Score: 0.005
-
Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. Hepatology. 2017 12; 66(6):1814-1825.
Score: 0.005
-
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS One. 2017; 12(10):e0185728.
Score: 0.005
-
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS One. 2017; 12(2):e0172159.
Score: 0.005